Sarepta shares plunge 30% as future of its gene therapy appears at risk

Sarepta Therapeutics shares plunged over 30% on Friday, extending year-to-date losses to over 87%, following reports that the FDA is considering pulling its gene therapy Elevidys from the market or requesting a voluntary halt to shipments. This potential action stems from an investigation into two patient deaths linked to Elevidys and a third death tied to another Sarepta gene therapy utilizing the same delivery method, intensifying safety concerns. The situation is critical for Sarepta as Elevidys accounts for over half of its net product revenue, and its efficacy has been controversial, making the drug's safety profile particularly scrutinized by regulators and investors.

Analysis

Sarepta Therapeutics (SRPT) is facing an existential threat following reports that the FDA is considering pulling its flagship gene therapy, Elevidys, from the market. This consideration, which has driven the stock down over 30% in a single day and more than 87% year-to-date, stems from an investigation into two patient deaths linked to the treatment and a third death in a trial for another gene therapy using the same delivery method. The situation is critically amplified by Elevidys's controversial efficacy profile; the drug previously failed to meet its primary goal in a Phase 3 trial and its expanded approval was granted by an FDA director overruling staff concerns. This uncertain benefit makes the reported safety events, including liver failure, exceptionally damaging to its risk-reward calculus, especially when compared to treatments like Novartis's Zolgensma, which has demonstrated clear benefits despite similar safety risks. With Elevidys accounting for over half of Sarepta's total net product revenue, a potential market withdrawal, as one BMO analyst noted, could render the company's business model unviable.

Key Decisions for Investors

• Given the severe safety concerns and the potential for a complete FDA-mandated withdrawal of Elevidys, which constitutes over 50% of revenue, investors should be prepared for significant further downside risk as this represents a fundamental threat to the company's viability.
• The primary catalyst for SRPT is the forthcoming official decision from the FDA; any position is highly speculative until there is clarity on whether the drug will be pulled, its label severely restricted, or allowed to remain on the market.
• Investors should recognize that this is a company-specific crisis tied directly to Elevidys's precarious risk-benefit profile and Sarepta's high financial dependency, rather than a broader biotech sector issue, necessitating a re-evaluation of exposure based on this idiosyncratic risk.